530-36-9

Basic information

• Product Name: 2-AMINO-1,2-DIPHENYL-ETHANOL
• Synonyms: 1-Amino-2-hydroxy-1,2-diphenylethane;NSC 10778;Ethanol, 2-amino-1,2-diphenyl-;TIMTEC-BB SBB000532;2-AMINO-1,2-DIPHENYL-ETHANOL;2-(Phenylamino)-2-phenylethanol;2-Phenyl-2-(phenylamino)ethanol;2-Phenyl-2-anilinoethanol
• CAS NO: 530-36-9
• Molecular Formula: C₁₄H₁₅NO
• Molecular Weight: 213.27
• Mol File: 530-36-9.mol
• Article Data: 44

Chemical Properties

• Melting Point: 165℃
• Boiling Point: 374.3°Cat760mmHg
• Flash Point: 180.2°C
• Appearance: /
• Density: 1.148
• PKA: 11.70±0.45(Predicted)
• CAS DataBase Reference: 2-AMINO-1,2-DIPHENYL-ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-1,2-DIPHENYL-ETHANOL(530-36-9)
• EPA Substance Registry System: 2-AMINO-1,2-DIPHENYL-ETHANOL(530-36-9)

Safety Data

• Hazardous Substances Data: 530-36-9(Hazardous Substances Data)

Usage

Purification Methods

Recrystallise the ethanol from EtOH. The 1R,2S-(-)-[23190-16-1] and the 1S,2R(+)-enantiomers also crystallise from EtOH and have m 142-145o, [ ] D ± 7o (c 0.6, EtOH). [Masters et al. J Org Chem 56 5666 1991, Masters & Hegedus J Org Chem 58 4547 1993, Beilstein 13 IV 2150.]

InChI:InChI=1/C14H15NO/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10,13-14,16H,15H2

Upstream product

• 64-17-5 ethanol 
• 87-69-4 L-Tartaric acid 
• 530-36-9 threo-1,2-diphenyl-2-aminoethan-1-ol 
• 441-38-3 benzoin oxime 
• 780-25-6 N-benzylidene benzylamine 
• 131350-15-7 N-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]formamide 
• 2935-35-5 (S)-2-phenylglycine 
• 572-45-2 benzil dioxime 
• 616-06-8 2-amino-hexanoic acid 
• 100-52-7 benzaldehyde 
• 617-65-2 Glutamic acid 
• 556-02-5 ?Tyr 
• 2835-06-5 phenylglycin 
• 59-51-8 DL-methionine 

Downstream Products

• 6275-45-2 dichloro-acetic acid-(α'-hydroxy-bibenzyl-α-ylamide) 
• 530-36-9 (1R,2R)-2-amino-1,2-diphenylethane-1-ol 
• 492-70-6 1,2-diphenyl-1,2-ethanediol 
• 530-36-9 (1S,2S)-2-amino-1,2-diphenylethanol 
• 530-36-9 2-amino-1,2-diphenylethanol 
• 6287-74-7 (+/-)-erythro-α'-(2-diethylamino-ethylamino)-bibenzyl-α-ol 
• 23364-44-5 (1S,2R)-2-Amino-1,2-diphenylethanol 
• 23190-16-1 (1R,2S)-2-Amino-1,2-diphenylethanol 
• 530-36-9 threo-1,2-diphenyl-2-aminoethan-1-ol 
• 49855-40-5 (+/-)-erythro-α'-chloro-bibenzylyl-(α)-amine 
• 49855-40-5 (+/-)-threo-α'-chloro-bibenzylyl-(α)-amine 
• 780-25-6 N-benzylidene benzylamine 
• 100-52-7 benzaldehyde 
• 100-46-9 benzylamine 

Relevant articles and documents

Site-Specific C(sp3)–H Aminations of Imidates and Amidines Enabled by Covalently Tethered Distonic Radical Anions

The utilization of N-centered radicals to synthesize nitrogen-containing compounds has attracted considerable attention recently, due to their powerful reactivities and the concomitant construction of C?N bonds. However, the generation and control of N-centered radicals remain particularly challenging. We report a tethering strategy using SOMO-HOMO-converted distonic radical anions for the site-specific aminations of imidates and amidines with aid of the non-covalent interaction. This reaction features a remarkably broad substrate scope and also enables the late-stage functionalization of bioactive molecules. Furthermore, the reaction mechanism is thoroughly investigated through kinetic studies, Raman spectroscopy, electron paramagnetic resonance spectroscopy, and density functional theory calculations, revealing that the aminations likely involve direct homolytic cleavage of N?H bonds and subsequently controllable 1,5 or 1,6 hydrogen atom transfer.

Large-scale preparation of key building blocks for the manufacture of fully synthetic macrolide antibiotics

Key building blocks for the production of fully synthetic macrolides have been scaled-up in first time pilot plant and kilo-lab campaigns. These building blocks have supported the discovery of new macrolide antibiotics as well as ongoing preclinical studies.

HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).